News Details

ARCSA announces sweeping reforms to manufacturing and operational standards as part of its 2026 regulatory agenda

 Ecuador's National Agency for Health Regulation, Control and Surveillance, known as ARCSA, has unveiled a series of significant regulatory reforms set to take effect throughout 2026, targeting the pharmaceutical supply chain, the medical devices industry, and the licensing of health-related businesses operating across the country.

The measures, laid out in the agency's Institutional Regulatory Plan, reflect growing concern within government circles about gaps in oversight that could leave Ecuadorian consumers exposed to substandard or improperly sourced health products.

1. Medicines at risk of shortage without stronger manufacturing oversight

At the heart of the reform package is a proposed update to the country's Good Manufacturing Practices framework for pharmaceuticals. ARCSA has identified what it describes as critical gaps in how risk-based criteria are applied during the certification and recognition of manufacturing facilities, gaps that, officials warn, could jeopardise the steady flow of medicines to patients nationwide.

The reform, expected to be submitted for approval in November 2026, seeks to harmonise and strengthen the criteria used when certifying pharmaceutical manufacturers, ensuring that products reaching the market consistently meet internationally recognised standards of quality, safety and efficacy. The agency has been explicit that no compromise on those core standards will be entertained in the process.

2. Medical device manufacturers face new certification demands

In a parallel move also scheduled for November, ARCSA intends to introduce an entirely new regulatory framework governing the manufacture of medical devices, medical equipment and biochemical reagents produced within Ecuador.

Currently, no dedicated certification standard exists for domestic manufacturers in this sector, a gap that the agency says has allowed products that fail to meet adequate quality and performance benchmarks to enter the national market. The new normative expected to be release in November 2026,  will establish binding guidelines for Good Manufacturing Practices specifically tailored to this industry, requiring producers to demonstrate compliance before their products can be commercially distributed.

The move is seen as particularly significant given the expanding role of locally produced medical technology in Ecuador's healthcare system, and comes amid broader regional efforts to reduce dependence on imported medical supplies.

3. Illegal imports and unlicensed businesses in the crosshairs

Perhaps the most immediate concern flagged in the regulatory plan relates to establishments operating under health surveillance without a valid or appropriate operating permit. ARCSA has identified this as a key vulnerability through which irregularly imported products, those that have not undergone proper sanitary control, are entering the Ecuadorian market undetected.

A partial reform to the existing operating permit framework, targeted for June 2026, would introduce stricter verification mechanisms to ensure businesses are correctly categorised and fully licensed before they are permitted to trade. The agency argues that without these controls, there is no reliable way to guarantee the safety of the products that consumers ultimately purchase.

The reform builds on a 2023 resolution that first set out the permit requirements for establishments subject to health oversight, but which officials now acknowledge left room for circumvention.

Taken together, the three reforms represent one of ARCSA's most ambitious regulatory pushes in recent years. The agency, which operates under Ecuador's Ministry of Public Health, has indicated that the plan is aligned with the United Nations Sustainable Development Goals, particularly those relating to good health, well-being and strong institutional frameworks.

The plan was formally approved on 3 March 2026, and is led by the agency's General Technical Coordination for Health Surveillance and Control Regulation.